|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX9 |
Gene summary for DHX9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX9 | Gene ID | 1660 |
| Gene name | DExH-box helicase 9 | |
| Gene Alias | DDX9 | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | B3KU66 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1660 | DHX9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.64e-02 | -3.07e-01 | 0.0155 |
| 1660 | DHX9 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.16e-02 | -1.61e-01 | -0.1001 |
| 1660 | DHX9 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.66e-09 | 5.75e-01 | 0.294 |
| 1660 | DHX9 | A015-C-203 | Human | Colorectum | FAP | 1.15e-17 | -2.52e-01 | -0.1294 |
| 1660 | DHX9 | A002-C-201 | Human | Colorectum | FAP | 7.88e-06 | -1.83e-01 | 0.0324 |
| 1660 | DHX9 | A002-C-203 | Human | Colorectum | FAP | 1.97e-02 | -1.28e-01 | 0.2786 |
| 1660 | DHX9 | A001-C-119 | Human | Colorectum | FAP | 6.00e-04 | -2.34e-01 | -0.1557 |
| 1660 | DHX9 | A001-C-108 | Human | Colorectum | FAP | 1.31e-11 | -2.87e-01 | -0.0272 |
| 1660 | DHX9 | A002-C-205 | Human | Colorectum | FAP | 5.84e-13 | -3.09e-01 | -0.1236 |
| 1660 | DHX9 | A015-C-006 | Human | Colorectum | FAP | 3.13e-08 | -2.44e-01 | -0.0994 |
| 1660 | DHX9 | A015-C-106 | Human | Colorectum | FAP | 1.14e-09 | -2.12e-01 | -0.0511 |
| 1660 | DHX9 | A002-C-114 | Human | Colorectum | FAP | 5.45e-11 | -3.06e-01 | -0.1561 |
| 1660 | DHX9 | A015-C-104 | Human | Colorectum | FAP | 5.70e-20 | -2.89e-01 | -0.1899 |
| 1660 | DHX9 | A001-C-014 | Human | Colorectum | FAP | 7.68e-09 | -2.11e-01 | 0.0135 |
| 1660 | DHX9 | A002-C-016 | Human | Colorectum | FAP | 1.61e-11 | -2.49e-01 | 0.0521 |
| 1660 | DHX9 | A015-C-002 | Human | Colorectum | FAP | 1.70e-06 | -2.55e-01 | -0.0763 |
| 1660 | DHX9 | A001-C-203 | Human | Colorectum | FAP | 3.43e-05 | -1.48e-01 | -0.0481 |
| 1660 | DHX9 | A002-C-116 | Human | Colorectum | FAP | 2.34e-22 | -3.38e-01 | -0.0452 |
| 1660 | DHX9 | A014-C-008 | Human | Colorectum | FAP | 2.02e-07 | -2.25e-01 | -0.191 |
| 1660 | DHX9 | A018-E-020 | Human | Colorectum | FAP | 1.19e-10 | -3.19e-01 | -0.2034 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20006379 | Thyroid | HT | positive regulation of gene silencing by miRNA | 7/1272 | 30/18723 | 3.35e-03 | 2.60e-02 | 7 |
| GO:004427024 | Thyroid | HT | cellular nitrogen compound catabolic process | 46/1272 | 451/18723 | 3.83e-03 | 2.84e-02 | 46 |
| GO:00601489 | Thyroid | HT | positive regulation of posttranscriptional gene silencing | 7/1272 | 31/18723 | 4.08e-03 | 2.99e-02 | 7 |
| GO:00028334 | Thyroid | HT | positive regulation of response to biotic stimulus | 21/1272 | 168/18723 | 4.98e-03 | 3.36e-02 | 21 |
| GO:00467823 | Thyroid | HT | regulation of viral transcription | 5/1272 | 19/18723 | 7.48e-03 | 4.44e-02 | 5 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0008380113 | Thyroid | PTC | RNA splicing | 273/5968 | 434/18723 | 4.44e-41 | 1.40e-37 | 273 |
| GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
| GO:0000375113 | Thyroid | PTC | RNA splicing, via transesterification reactions | 202/5968 | 324/18723 | 6.81e-30 | 3.91e-27 | 202 |
| GO:0000377113 | Thyroid | PTC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:0000398113 | Thyroid | PTC | mRNA splicing, via spliceosome | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:1903311112 | Thyroid | PTC | regulation of mRNA metabolic process | 181/5968 | 288/18723 | 1.60e-27 | 5.94e-25 | 181 |
| GO:0032386111 | Thyroid | PTC | regulation of intracellular transport | 202/5968 | 337/18723 | 1.12e-26 | 3.93e-24 | 202 |
| GO:0016032113 | Thyroid | PTC | viral process | 236/5968 | 415/18723 | 2.48e-26 | 8.24e-24 | 236 |
| GO:0006913112 | Thyroid | PTC | nucleocytoplasmic transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
| GO:0051169112 | Thyroid | PTC | nuclear transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
| GO:0032388112 | Thyroid | PTC | positive regulation of intracellular transport | 132/5968 | 202/18723 | 1.10e-22 | 2.57e-20 | 132 |
| GO:0006403112 | Thyroid | PTC | RNA localization | 130/5968 | 201/18723 | 9.23e-22 | 1.94e-19 | 130 |
| GO:0050684112 | Thyroid | PTC | regulation of mRNA processing | 98/5968 | 137/18723 | 1.53e-21 | 3.10e-19 | 98 |
| GO:0006401112 | Thyroid | PTC | RNA catabolic process | 163/5968 | 278/18723 | 2.13e-20 | 3.27e-18 | 163 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX9 | SNV | Missense_Mutation | novel | c.1531N>T | p.Asp511Tyr | p.D511Y | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| DHX9 | SNV | Missense_Mutation | c.2173N>T | p.Val725Phe | p.V725F | Q08211 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX9 | SNV | Missense_Mutation | c.3280C>T | p.His1094Tyr | p.H1094Y | Q08211 | protein_coding | tolerated(1) | benign(0.157) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DHX9 | SNV | Missense_Mutation | c.2714G>A | p.Arg905Gln | p.R905Q | Q08211 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX9 | SNV | Missense_Mutation | novel | c.2202N>C | p.Gln734His | p.Q734H | Q08211 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | rs754675901 | c.1582C>T | p.Arg528Cys | p.R528C | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | c.176G>A | p.Ser59Asn | p.S59N | Q08211 | protein_coding | tolerated(0.22) | benign(0.281) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DHX9 | SNV | Missense_Mutation | novel | c.929N>G | p.Leu310Arg | p.L310R | Q08211 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | c.2588G>A | p.Arg863His | p.R863H | Q08211 | protein_coding | deleterious(0.05) | probably_damaging(0.993) | TCGA-D8-A1JE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamicin | SD | |
| DHX9 | SNV | Missense_Mutation | c.67N>G | p.Ile23Val | p.I23V | Q08211 | protein_coding | tolerated(0.92) | benign(0.028) | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |